Factor XIII (FXIII) is unique among clotting factors for a number of reasons: 1) it is a
protransglutaminase, which becomes activated in the last stage of coagulation; 2) it works …

Factor XIII (FXIII) is a transglutaminase enzyme that catalyses the formation of ε-(γ-glutamyl)
lysyl isopeptide bonds into protein substrates. The plasma form, FXIIIA2B2, has an …

As the third most common vascular disease, venous thromboembolism is associated with
significant mortality and morbidity. Pathogenesis underlying venous thrombosis is still not …

The article discusses guidelines from the United Kingdom Haemophilia Centre Doctors'
Organisation (UKHCDO) on diagnosis and management of acquired coagulation inhibitors …

Liver transplantation in cirrhotic patients is accompanied by severe bleeding. Indeed, the
first 100 recipients of liver allografts transplanted by Thomas E. Starzl died mainly by …

Factor XIII (FXIII) deficiency is a rare hemorrhagic disorder for which the highest incidence
occurs in southeast Iran. The aim of this study was to assess molecular characteristics …

The generation of tissue-engineered blood vessel substitutes remains an ongoing challenge
for cardiovascular tissue engineering. Full biocompatibility and immediate availability have …

Fibrin clot formation is a key event in the development of thrombotic disease and is the final
step in a multifactor coagulation cascade. Fibrinogen is a large glycoprotein that forms the …

Coagulation factor XIII (FXIII), a plasma transglutaminase, is best known as the final enzyme
in the coagulation cascade, where it is responsible for cross-linking of fibrin. However, a …

Factor XIII deficiency (FXIIID) is a rare bleeding disorder with an estimated prevalence of 1 in
2-million population worldwide. In Iran, a Middle Eastern country with a high rate of …